SuperworthIB Acquisition EPS IBAC
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$0.03
- Latest quarter, Q3 FY26
- −$0.11
- −320% on a year earlier
- Fiscal year 2025
- $0.36
- +57% on the year before
IB Acquisition's earnings per share was −$0.03 over the twelve months to Jun 30, 2026, down 108% on a year earlier.
In its latest quarter, Q3 FY26, it was −$0.11, down 320% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.36 | +57% |
| FY2024 | $0.23 | n/a |
| FY2023 | $0.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$0.11 | −320% | −$0.03 | |
| Q2 FY26 | −$0.11 | −320% | $0.13 | |
| Q1 FY26 | −$0.01 | −117% | $0.29 | |
| Q4 FY25 | $0.20 | −17% | $0.36 | |
| Q3 FY25 | $0.05 | −29% | $0.40 | |
| Q2 FY25 | $0.05 | n/a | $0.42 | |
| Q1 FY25 | $0.06 | n/a | $0.32 | |
| Q4 FY24 | $0.24 | n/a | $0.23 | |
| Q3 FY24 | $0.07 | n/a | −$0.01 | |
| Q2 FY24 | −$0.05 | n/a | −$0.08 | |
| Q1 FY24 | −$0.03 | n/a | −$0.03 | |
| Q4 FY23 | $0.00 | n/a | $0.00 |
Against its peers
Companies in Healthcare nearest IB Acquisition's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| IBACIB Acquisition | −$0.03 | −108% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NEPHNephros | $0.16 | +33% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on IB Acquisition
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.